Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.
Eli Lilly & Co.'s Verzenio (abemaciclib), now approved for breast cancer, will compete for market share in a crowded category that already includes two rival cyclin dependent kinase 4/6 (CDK4/6) inhibitors – Pfizer Inc.'s well-entrenched Ibrance (palbociclib) and Novartis AG's newcomer Kisqali (ribociclib) – but it isn't setting out to do so based on price.
The US FDA approved Verzenio on Sept
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
As CEO Anderson backs high prices for innovative drugs in Europe
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
